Long-term survival and biomarkers of immunotherapy in small cell lung cancer: a systematic review.

Transl Lung Cancer Res · 2026 · PMC13263851 · PMID 42291341

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Surprisingly, in the phase III CASPIAN the patients with brain metastases did obtain a benefit in OS from the addition of durvalumab, and a clear trend was observed in the randomized trial ASTRUM-005 with serplulimab ( 3 , 5 ).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.